TCM
KYMR icon

TimesSquare Capital Management’s Kymera Therapeutics KYMR Stock Holding History

TimesSquare Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18M Sell
157,327
-11,519
-7% -$990K 0.27% 108
2026
Q1 		$14.1M Sell
168,846
-21,054
-11% -$1.67M 0.24% 122
2025
Q4 		$14.8M Buy
+189,900
New +$12.8M 0.22% 128

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TimesSquare Capital Management's KYMR Position: Q2 2026 in Review

TimesSquare Capital Management reduced its Kymera Therapeutics (KYMR) stake by 6.8% in Q2 2026, selling an estimated $990K and leaving 157,327 shares worth $18M. The position accounts for 0.27% of the portfolio, ranked #108.

TimesSquare Capital Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • TimesSquare Capital Management held 157,327 shares of Kymera Therapeutics worth $18M as of Q2 2026.
  • TimesSquare Capital Management sold 11,519 Kymera Therapeutics shares in Q2 2026, an estimated $990K.
  • Kymera Therapeutics made up 0.27% of TimesSquare Capital Management's portfolio in Q2 2026, its #108 holding.
  • TimesSquare Capital Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.